Trial Profile

A Phase II double blind randomized clinical trial of ACP-01 as a treatment of ischemic cardiomyopathy

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 01 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ACP 01 (Primary)
Indications Cardiomyopathies; Dilated cardiomyopathy
Focus Therapeutic Use

Most Recent Events

29 Aug 2023 According to a Hemostemix media release, company drafted a clinical trial protocol for this study which will be submitted to regulators shortly.
27 Jan 2023 New trial record
19 Jan 2023 According to a Hemostemix media release, the company and the MUHC Foundation are committed to working together with federal and provincial partners alongside donors to fund the trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com